Compare AVY & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVY | MDGL |
|---|---|---|
| Founded | 1935 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 11.5B |
| IPO Year | 1994 | 2005 |
| Metric | AVY | MDGL |
|---|---|---|
| Price | $187.99 | $427.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $203.30 | ★ $688.78 |
| AVG Volume (30 Days) | ★ 582.2K | 526.8K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | ★ 0.69 | N/A |
| EPS | ★ 7.09 | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $5.95 | $65.40 |
| Revenue Next Year | $2.76 | $37.87 |
| P/E Ratio | $26.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $152.42 | $353.54 |
| 52 Week High | $199.54 | $615.00 |
| Indicator | AVY | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 60.88 | 40.94 |
| Support Level | $165.09 | $416.21 |
| Resistance Level | $197.47 | $553.95 |
| Average True Range (ATR) | 4.45 | 24.52 |
| MACD | -0.08 | 3.61 |
| Stochastic Oscillator | 57.76 | 54.17 |
Avery Dennison Corp provides materials science and digital identification solutions, offering labeling and functional materials, RFID inlays and tags, software connecting physical and digital, and products that enhance packaging and customer experience. Serving industries including retail, apparel, e-commerce, logistics, food, pharmaceuticals, and automotive it operates through two reportable segments: Materials Group, which manufactures and sells pressure-sensitive label materials, graphics, reflective products, performance tapes, and other adhesive solutions, and earns the majority of revenue; and Solutions Group, which provides brand and price tickets, tags, labels with RFID inlays, and related services, supplies, and equipment.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.